BioMarin Pharmaceutical Company Profile (NASDAQ:BMRN)

About BioMarin Pharmaceutical

BioMarin Pharmaceutical logoBioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company's product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Its products in clinical development include Kyndrisa, Pegvaliase, Reveglucosidase alfa, Vosoritide (formerly BMN 111), Cerliponase alfa, BMN 044, BMN 045, BMN 053 and BMN 270. Vimizim is an enzyme replacement therapy for the treatment of mucopolysaccharidosis type IV (MPS IV A). Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) indicated for patients with mucopolysaccharidosis VI (MPS VI). Kuvan is a synthetic oral form of 6R-BH4 indicated for patients with phenylketonuria (PKU).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BMRN
  • CUSIP: 09061G10
Key Metrics:
  • Previous Close: $97.45
  • 50 Day Moving Average: $95.47
  • 200 Day Moving Average: $88.47
  • 52-Week Range: $163,465,000.00 - $62.12
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -91.89
  • P/E Growth: -0.99
  • Market Cap: $15.92B
  • Outstanding Shares: 163,465,000
  • Beta: 1.13
  • Net Margins: -54.53%
  • Return on Equity: -11.99%
  • Return on Assets: -7.57%
  • Debt-to-Equity Ratio: 0.34%
  • Current Ratio: 3.03%
  • Quick Ratio: 2.14%
Additional Links:
Companies Related to BioMarin Pharmaceutical:

Analyst Ratings

Consensus Ratings for BioMarin Pharmaceutical (NASDAQ:BMRN) (?)
Ratings Breakdown: 2 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $121.71 (24.95% upside)

Analysts' Ratings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
DateFirmActionRatingPrice TargetDetails
9/16/2016Leerink SwannReiterated RatingOutperform$127.00View Rating Details
9/8/2016Cowen and CompanySet Price TargetBuy$150.00View Rating Details
9/7/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
9/6/2016WedbushReiterated RatingNeutral$108.00 -> $104.00View Rating Details
8/19/2016Piper Jaffray Cos.Reiterated RatingOverweightView Rating Details
8/17/2016Jefferies GroupReiterated RatingBuyView Rating Details
8/8/2016Credit Suisse Group AGSet Price TargetBuy$111.00View Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$107.00 -> $113.00View Rating Details
8/5/2016Barclays PLCBoost Price TargetOverweight$105.00 -> $125.00View Rating Details
7/28/2016William BlairSet Price TargetBuy$116.00View Rating Details
7/28/2016Robert W. BairdBoost Price TargetOutperform$110.00 -> $115.00View Rating Details
6/20/2016Oppenheimer Holdings Inc.Reiterated RatingMarket Perform$99.00View Rating Details
6/1/2016Goldman Sachs Group Inc.Reiterated RatingBuy$126.00View Rating Details
5/31/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
4/7/2016BMO Capital MarketsInitiated CoverageOutperform$99.00View Rating Details
1/15/2016Bank of America Corp.Reiterated RatingBuy$165.00 -> $135.00View Rating Details
10/13/2015Raymond James Financial Inc.Reiterated RatingOutperform$157.00View Rating Details
8/6/2015Deutsche Bank AGReiterated RatingBuy$160.00View Rating Details
8/4/2015NomuraReiterated RatingBuy$163.00 -> $173.00View Rating Details
8/4/2015SunTrust Banks Inc.Reiterated RatingBuyView Rating Details
6/18/2015Canaccord GenuityBoost Price TargetBuy$115.00 -> $150.00View Rating Details
2/26/2015Brean CapitalReiterated RatingHoldView Rating Details
2/26/2015Citigroup Inc.Reiterated RatingBuy$94.00 -> $133.00View Rating Details
1/29/2015Evercore ISIInitiated CoverageBuyView Rating Details
11/3/2014Wells Fargo & Co.UpgradeMarket Perform -> OutperformView Rating Details
(Data available from 9/26/2014 forward)


Earnings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.52)($2.61)$278.75 million$300.10 millionViewN/AView Earnings Details
4/28/2016Q116($0.85)($0.53)$240.21 million$236.70 millionViewListenView Earnings Details
2/25/2016Q415$0.67$0.39$224.14 million$227.90 millionViewListenView Earnings Details
10/29/2015Q315($0.65)($0.60)$216.32 million$208.90 millionViewListenView Earnings Details
8/3/2015Q215($0.53)($0.51)$218.16 million$250.50 millionViewN/AView Earnings Details
4/30/2015Q1($0.53)($0.43)$201.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.59)($0.47)$189.01 million$230.90 millionViewN/AView Earnings Details
10/23/2014Q314($0.22)($0.16)$206.00 million$176.80 millionViewListenView Earnings Details
7/30/2014Q214($0.41)($0.23)$159.70 million$191.70 millionViewN/AView Earnings Details
5/1/2014($0.44)($0.01)$145.16 million$151.60 millionViewN/AView Earnings Details
2/26/2014Q413($0.35)($0.11)$146.07 million$146.90 millionViewN/AView Earnings Details
10/24/2013Q313($0.30)($0.38)$140.00 million$136.90 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.29)($0.16)$134.33 million$136.80 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.30)($0.31)$131.35 million$127.90 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.22)($0.43)$129.70 million$130.96 millionViewN/AView Earnings Details
10/25/2012($0.20)($0.04)ViewN/AView Earnings Details
8/1/2012($0.19)($0.27)ViewN/AView Earnings Details
4/26/2012($0.15)($0.21)ViewN/AView Earnings Details
2/16/2012($0.10)($0.23)ViewN/AView Earnings Details
10/27/2011($0.10)($0.16)ViewN/AView Earnings Details
7/28/2011($0.09)($0.05)ViewN/AView Earnings Details
4/28/2011($0.10)$0.14ViewN/AView Earnings Details
2/17/2011($0.02)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)
Current Year EPS Consensus Estimate: $-3.95 EPS
Next Year EPS Consensus Estimate: $-1.06 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($2.51)($0.40)($0.94)
Q2 20166($4.02)($0.27)($2.11)
Q3 20166($0.63)($0.24)($0.43)
Q4 20165($0.67)($0.26)($0.51)
Q1 20171($0.44)($0.44)($0.44)
Q2 20171($0.25)($0.25)($0.25)
Q3 20171($0.31)($0.31)($0.31)
Q4 20171($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)


Dividend History for BioMarin Pharmaceutical (NASDAQ:BMRN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Insider Ownership Percentage: 2.50%
Institutional Ownership Percentage: 93.02%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/16/2016Jean Jacques BienaimeCEOSell137,368$95.34$13,096,665.12View SEC Filing  
8/26/2016Henry J FuchsEVPSell15,000$95.06$1,425,900.00View SEC Filing  
8/16/2016Jean Jacques BienaimeCEOSell41,666$91.49$3,812,022.34View SEC Filing  
8/1/2016Brian MuellerVPSell287$100.00$28,700.00View SEC Filing  
8/1/2016Daniel K SpiegelmanCFOSell4,000$99.33$397,320.00View SEC Filing  
8/1/2016George Eric DavisEVPSell2,167$100.00$216,700.00View SEC Filing  
7/27/2016V Bryan LawlisDirectorSell1,100$95.39$104,929.00View SEC Filing  
7/22/2016V Bryan LawlisDirectorSell6,400$95.01$608,064.00View SEC Filing  
7/18/2016Jean Jacques BienaimeCEOSell41,666$92.72$3,863,271.52View SEC Filing  
7/7/2016George Eric DavisEVPSell2,167$90.00$195,030.00View SEC Filing  
6/20/2016V Bryan LawlisDirectorSell550$82.77$45,523.50View SEC Filing  
6/16/2016Jean Jacques BienaimeCEOSell41,666$80.55$3,356,196.30View SEC Filing  
6/6/2016Daniel K SpiegelmanCFOSell1,649$89.14$146,991.86View SEC Filing  
5/31/2016Daniel K SpiegelmanCFOSell20,841$89.88$1,873,189.08View SEC Filing  
5/26/2016Henry J FuchsEVPSell15,000$87.81$1,317,150.00View SEC Filing  
5/23/2016Daniel K SpiegelmanCFOSell3,769$87.07$328,166.83View SEC Filing  
5/18/2016Robert BaffiEVPSell5,000$87.05$435,250.00View SEC Filing  
5/10/2016George Eric DavisEVPSell14,658$85.11$1,247,542.38View SEC Filing  
5/5/2016Jean Jacques BienaimeCEOSell50,000$80.15$4,007,500.00View SEC Filing  
5/3/2016Jeffrey Robert AjerEVPSell415$86.03$35,702.45View SEC Filing  
5/2/2016Jean Jacques BienaimeCEOSell36,500$85.01$3,102,865.00View SEC Filing  
3/14/2016George Eric DavisEVPSell1,996$86.21$172,075.16View SEC Filing  
3/4/2016Jeffrey Robert AjerSVPSell1,255$88.42$110,967.10View SEC Filing  
3/2/2016Daniel K SpiegelmanCFOSell4,623$86.12$398,132.76View SEC Filing  
3/1/2016Jean Jacques BienaimeCEOSell10,000$84.28$842,800.00View SEC Filing  
2/22/2016Michael G GreyDirectorSell7,500$80.00$600,000.00View SEC Filing  
12/16/2015George Eric DavisSVPSell1,362$100.00$136,200.00View SEC Filing  
11/30/2015Jean Jacques BienaimeCEOSell1,000$94.74$94,740.00View SEC Filing  
11/16/2015Daniel K. SpiegelmanCFOSell20,000$104.30$2,086,000.00View SEC Filing  
11/16/2015V Bryan LawlisDirectorSell8,550$106.90$913,995.00View SEC Filing  
10/15/2015Jean Jacques BienaimeCEOSell1,000$108.24$108,240.00View SEC Filing  
9/14/2015Jean Jacques BienaimeCEOSell1,000$131.43$131,430.00View SEC Filing  
7/20/2015Jeffrey Robert AjerSVPSell3,000$150.00$450,000.00View SEC Filing  
7/7/2015Jean Jacques BienaimeCEOSell1,500$139.07$208,605.00View SEC Filing  
6/5/2015Daniel K SpiegelmanCFOSell1,649$122.30$201,672.70View SEC Filing  
6/5/2015Henry J FuchsEVPSell1,864$122.32$228,004.48View SEC Filing  
6/4/2015Jeffrey Robert AjerSVPSell1,362$122.35$166,640.70View SEC Filing  
6/1/2015Daniel K SpiegelmanCFOSell5,523$124.73$688,883.79View SEC Filing  
6/1/2015Jeffrey Robert AjerSVPSell377$123.76$46,657.52View SEC Filing  
5/29/2015Daniel K SpiegelmanCFOSell1,578$126.15$199,064.70View SEC Filing  
5/26/2015Jeffrey Robert AjerSVPSell1,625$126.55$205,643.75View SEC Filing  
5/18/2015Daniel K SpiegelmanCFOSell2,059$124.77$256,901.43View SEC Filing  
5/18/2015George Eric DavisSVPSell2,558$125.26$320,415.08View SEC Filing  
5/18/2015Henry J FuchsEVPSell1,864$124.78$232,589.92View SEC Filing  
5/13/2015Henry J FuchsEVPSell1,434$121.37$174,044.58View SEC Filing  
5/11/2015Henry J FuchsEVPSell2,869$121.64$348,985.16View SEC Filing  
3/17/2015Jean Jacques BienaimeCEOSell2,000$124.17$248,340.00View SEC Filing  
3/16/2015Henry J FuchsEVPSell41,315$123.57$5,105,294.55View SEC Filing  
3/16/2015Jean Jacques BienaimeCEOSell1,000$123.48$123,480.00View SEC Filing  
3/10/2015Jean Jacques BienaimeCEOSell21,021$112.39$2,362,550.19View SEC Filing  
3/9/2015Jean Jacques BienaimeCEOSell19,000$112.13$2,130,470.00View SEC Filing  
3/5/2015Jean Jacques BienaimeCEOSell10,000$113.70$1,137,000.00View SEC Filing  
3/5/2015Robert BaffiEVPSell14,051$116.37$1,635,114.87View SEC Filing  
3/4/2015Jean Jacques BienaimeCEOSell13,916$107.92$1,501,814.72View SEC Filing  
3/3/2015Jean Jacques BienaimeCEOSell5,000$107.42$537,100.00View SEC Filing  
3/2/2015Daniel K SpiegelmanCFOSell15,500$107.00$1,658,500.00View SEC Filing  
3/2/2015George Eric DavisSVPSell23,000$108.31$2,491,130.00View SEC Filing  
3/2/2015Jean Jacques BienaimeCEOSell5,000$108.44$542,200.00View SEC Filing  
1/9/2015Jean Jacques BienaimeCEOSell2,000$94.14$188,280.00View SEC Filing  
12/24/2014Jean Jacques BienaimeCEOSell5,000$88.73$443,650.00View SEC Filing  
12/10/2014Jean Jacques BienaimeCEOSell2,000$95.00$190,000.00View SEC Filing  
12/4/2014Alan LewisDirectorSell7,500$89.90$674,250.00View SEC Filing  
12/2/2014Brian MuellerVPSell11,950$90.91$1,086,374.50View SEC Filing  
11/25/2014George Eric DavisSVPSell20,000$89.75$1,795,000.00View SEC Filing  
11/25/2014Jean Jacques BienaimeCEOSell2,000$90.00$180,000.00View SEC Filing  
11/12/2014Jean Jacques BienaimeCEOSell1,000$81.51$81,510.00View SEC Filing  
11/10/2014Henry J FuchsEVPSell20,000$86.55$1,731,000.00View SEC Filing  
11/10/2014Jean Jacques BienaimeCEOSell4,000$87.00$348,000.00View SEC Filing  
11/3/2014Jean Jacques BienaimeCEOSell3,000$85.33$255,990.00View SEC Filing  
11/3/2014Jeffrey Robert AjerSVPSell47$83.54$3,926.38View SEC Filing  
10/30/2014Robert BaffiEVPSell75,425$81.34$6,135,069.50View SEC Filing  
10/24/2014Jean Jacques BienaimeCEOSell2,000$80.00$160,000.00View SEC Filing  
9/19/2014George Eric DavisSVPSell17,536$69.75$1,223,136.00View SEC Filing  
9/2/2014Daniel K SpiegelmanCFOSell16,000$69.83$1,117,280.00View SEC Filing  
8/20/2014Jean Jacques BienaimeCEOSell5,000$70.00$350,000.00View SEC Filing  
8/5/2014Henry J FuchsEVPSell10,000$65.00$650,000.00View SEC Filing  
8/1/2014Daniel K SpiegelmanCFOSell2,229$61.76$137,663.04View SEC Filing  
7/2/2014Daniel K SpiegelmanCFOSell2,229$64.00$142,656.00View SEC Filing  
6/4/2014Jean Jacques BienaimeCEOSell2,000$61.20$122,400.00View SEC Filing  
5/22/2014Jean Jacques BienaimeCEOSell1,000$56.88$56,880.00View SEC Filing  
5/21/2014Jean Jacques BienaimeCEOSell1,545$56.19$86,813.55View SEC Filing  
5/16/2014Henry FuchsEVPSell1,864$56.86$105,987.04View SEC Filing  
5/16/2014Jeffrey Robert AjerSVPSell1,004$56.91$57,137.64View SEC Filing  
5/16/2014V Bryan LawlisDirectorSell1,700$56.87$96,679.00View SEC Filing  
5/13/2014Henry FuchsEVPSell1,434$58.23$83,501.82View SEC Filing  
5/9/2014Henry FuchsEVPSell3,479$57.91$201,468.89View SEC Filing  
2/3/2014Henry FuchsEVPSell10,000$67.70$677,000.00View SEC Filing  
12/24/2013Jean Jacques BienaimeCEOSell10,000$68.71$687,100.00View SEC Filing  
12/5/2013Jean Jacques BienaimeCEOSell5,000$69.70$348,500.00View SEC Filing  
10/16/2013Jean Jacques BienaimeCEOSell2,000$67.73$135,460.00View SEC Filing  
10/10/2013Jean Jacques BienaimeCEOSell3,000$66.76$200,280.00View SEC Filing  
9/19/2013Henry FuchsEVPSell10,000$80.19$801,900.00View SEC Filing  
9/16/2013Jean Jacques BienaimeCEOSell2,000$73.08$146,160.00View SEC Filing  
9/9/2013Robert BaffiEVPSell20,000$73.00$1,460,000.00View SEC Filing  
9/5/2013Henry J FuchsEVPSell10,000$70.00$700,000.00View SEC Filing  
9/4/2013Daniel K SpiegelmanCFOSell9,000$69.00$621,000.00View SEC Filing  
8/15/2013Jean Jacques BienaimeCEOSell1,000$64.36$64,360.00View SEC Filing  
7/1/2013Daniel K SpiegelmanCFOSell4,066$59.78$243,065.48View SEC Filing  
7/1/2013Henry J FuchsEVPSell10,000$60.00$600,000.00View SEC Filing  
6/3/2013Henry J FuchsEVPSell1,098$58.32$64,035.36View SEC Filing  
5/23/2013Henry J FuchsEVPSell20,609$66.29$1,366,170.61View SEC Filing  
5/22/2013Mark WoodVPSell3,103$67.12$208,273.36View SEC Filing  
5/21/2013Jean Jacques BienaimeCEOSell2,000$64.14$128,280.00View SEC Filing  
5/16/2013Jean Jacques BienaimeCEOSell12,000$67.90$814,800.00View SEC Filing  
5/14/2013Brian MuellerVPSell4,947$70.35$348,021.45View SEC Filing  
5/14/2013George Eric DavisSVPSell20,000$70.34$1,406,800.00View SEC Filing  
5/14/2013Jean Jacques BienaimeCEOSell15,000$70.17$1,052,550.00View SEC Filing  
5/13/2013Jean Jacques BienaimeCEOSell15,800$68.77$1,086,566.00View SEC Filing  
5/13/2013Jeffrey Robert AjerSVPSell1,248$69.26$86,436.48View SEC Filing  
5/8/2013Jean Jacques BienaimeCEOSell4,000$65.87$263,480.00View SEC Filing  
5/2/2013Jean Jacques BienaimeCEOSell3,000$64.99$194,970.00View SEC Filing  
4/10/2013Robert BaffiEVPSell20,000$64.00$1,280,000.00View SEC Filing  
3/22/2013Mark WoodVPSell3,103$60.21$186,831.63View SEC Filing  
3/4/2013George Eric DavisSVPSell4,000$60.18$240,720.00View SEC Filing  
2/22/2013Mark WoodVPSell3,103$55.22$171,347.66View SEC Filing  
2/4/2013Jean Jacques BienaimeCEOSell2,000$55.77$111,540.00View SEC Filing  
12/27/2012Jean Jacques BienaimeCEOSell17,000$48.37$822,290.00View SEC Filing  
11/12/2012George Eric DavisSVPSell99,075$48.45$4,800,183.75View SEC Filing  
9/4/2012Henry J FuchsEVPSell5,000$37.76$188,800.00View SEC Filing  
8/22/2012Mark WoodVPSell2,665$37.93$101,083.45View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for BioMarin Pharmaceutical (NASDAQ:BMRN)
News IconAnalysts Take the Wheel on BioMarin Pharmaceutical Inc. (NASDAQ ... - Frisco Fastball (NASDAQ:BMRN) - September 25 at 3:38 PM
News IconIntraday Active Biotech Stocks News: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), BioCryst Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:BMRN) - September 23 at 3:21 PM
News IconBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from Biotechnology – Todays Top Gains (NASDAQ:BMRN) - September 22 at 4:03 PM logoBioMarin Pharma (BMRN) Will Seek Review of PTAB Exon 51 Composition of Matter Patent Decision (SRPT) (NASDAQ:BMRN) - September 22 at 8:07 AM logoBMRN To Seek Review Of PTAB Ruling, CERC Awaits Phase 2 Data In Nov, OCRX Abuzz (NASDAQ:BMRN) - September 22 at 8:07 AM
News IconLeading stocks in today’s market: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) (NASDAQ:BMRN) - September 22 at 8:07 AM logoBioMarin Pharma (BMRN) Will Seek Review of PTAB Exon 51 ... - (NASDAQ:BMRN) - September 21 at 3:20 PM logoBioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics (NASDAQ:BMRN) - September 21 at 3:20 PM logoPatent Trial And Appeal Board Hands Sarepta Another Big Win (NASDAQ:BMRN) - September 21 at 3:20 PM logoSarepta Therapeutics: BioMarin Still Wants a Piece of the Action (NASDAQ:BMRN) - September 21 at 3:20 PM logoSarepta (SRPT) Stock Lower, BioMarin to Appeal Patent Ruling (NASDAQ:BMRN) - September 21 at 3:20 PM
News IconAnalysts Valuations For Two Stocks: Amphenol (NYSE:APH), BioMarin Pharmaceutical (NASDAQ:BMRN) - The Voice Registrar (NASDAQ:BMRN) - September 21 at 8:26 AM logoDoes Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy? (NASDAQ:BMRN) - September 21 at 8:26 AM logo[$$] Sarepta Soars 100% in a Week Yet Remains a Buy (NASDAQ:BMRN) - September 21 at 8:26 AM logoSarepta Shares Continue Rally As Analysts Flip To Positive (NASDAQ:BMRN) - September 20 at 4:36 PM
News IconBiotech news that matter for investors: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Progenics Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:BMRN) - September 20 at 9:47 AM
News IconTime To Put On The Watch List? – BioMarin Pharmaceutical Inc ... - The Voice Registrar (NASDAQ:BMRN) - September 20 at 9:47 AM logoBiomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $–'.– million of Shares - (NASDAQ:BMRN) - September 20 at 9:47 AM logoBiomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $13.1 million of Shares (NASDAQ:BMRN) - September 20 at 9:47 AM logoBiotech Stock Mailbag: Sarepta Therapeutics Approval Edition (NASDAQ:BMRN) - September 20 at 9:47 AM logoBioMarin Pharmaceutical : Announces Public Offering of Common Stock (NASDAQ:BMRN) - September 19 at 4:46 PM
News IconHigh Market Cap Stock of the Day – BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) (NASDAQ:BMRN) - September 19 at 4:46 PM
News IconBiotech Companies To Look Out For: ACADIA Pharmaceuticals Inc. (ACAD), BioMarin Pharmaceutical Inc. (BMRN) - The Independent Republic (NASDAQ:BMRN) - September 19 at 8:40 AM logoBiomarin Pharmaceutical Inc (BMRN) Affirmed at Outperform on Recent EMA Validation: Leerink - TCC (NASDAQ:BMRN) - September 17 at 3:50 PM logoBiomarin Pharmaceutical Inc (BMRN) Affirmed at Outperform on Recent EMA Validation: Leerink - TCC (NASDAQ:BMRN) - September 17 at 3:50 PM logoBioMarin Pharmaceutical Set to Possibly Pullback After Yesterday's Rally of 1.76% (NASDAQ:BMRN) - September 16 at 3:50 PM logoBiomarin Pharmaceutical Inc (BMRN) Affirmed at Outperform on Recent EMA Validation: Leerink (NASDAQ:BMRN) - September 16 at 12:27 PM
News IconIs BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a large market cap stock a smart buy? (NASDAQ:BMRN) - September 16 at 12:27 PM
News IconBiotech news that matter for investors: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Tesaro, Inc. (NASDAQ:TSRO) - The Voice Registrar (NASDAQ:BMRN) - September 15 at 3:42 PM logoBioMarin Pharma's (BMRN) MAA for Brineura in CLN2 Disease Validated by EMA - (NASDAQ:BMRN) - September 15 at 3:42 PM logoBioMarin Reports EMA Validation Of Brineura MAA For Treatment Of CLN2 Disease (NASDAQ:BMRN) - September 15 at 12:47 PM logoBioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application … (NASDAQ:BMRN) - September 15 at 12:47 PM logo8:39 am BioMarin Pharm: EMA validates the Marketing Authorization Application for Brineura to treat children with CLN2 disease (NASDAQ:BMRN) - September 15 at 12:47 PM logoBioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease (NASDAQ:BMRN) - September 15 at 12:47 PM logoBioMarin Pharmaceutical, Inc. – Value Analysis (NASDAQ:BMRN) : September 15, 2016 (NASDAQ:BMRN) - September 15 at 12:47 PM logoSarepta Therapeutics: Wait, I Thought Turmoil at the FDA Was Good News? (NASDAQ:BMRN) - September 15 at 12:47 PM logoSunTrust On Sarepta Therapeutics: FDA Likely To Deny Approval For Eteplirsen - Benzinga (NASDAQ:BMRN) - September 14 at 3:53 PM logoThese 5 Biotech Stocks Are Ready for a Volatility Break (NASDAQ:BMRN) - September 14 at 3:53 PM logoBioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : September 14, 2016 (NASDAQ:BMRN) - September 14 at 3:53 PM logo[$$] Sarepta Rally Has Legs as FDA Critic Leaves Agency (NASDAQ:BMRN) - September 14 at 3:53 PM logoLow Valuation Ratios Lead to Strong Portfolio Returns (NASDAQ:BMRN) - September 13 at 5:30 PM
News IconStock Trading Above Moving Averages: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Post News (NASDAQ:BMRN) - September 12 at 3:48 PM
News IconActive biotech company shares in the news: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Vertex Pharmaceuticals ... - The Voice Registrar (NASDAQ:BMRN) - September 12 at 3:48 PM
News IconStock on the Rise Over the Last Half Year: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Post News (NASDAQ:BMRN) - September 12 at 8:39 AM
News IconScorching Hot Biotech Stocks Tape: ZIOPHARM Oncology, Inc. (ZIOP), BioMarin Pharmaceutical Inc. (BMRN) - National Daily Press (NASDAQ:BMRN) - September 10 at 3:46 PM
News IconPlacing BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Under the Microscope (NASDAQ:BMRN) - September 9 at 3:48 PM
News IconPlacing BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Under the Microscope - National Daily Press (NASDAQ:BMRN) - September 9 at 8:45 AM logoBioMarin Announces Two Oral and 16 Poster Presentations at Society for the Study of Inborn Errors of Metabolism 2016 Annual Meeting (NASDAQ:BMRN) - September 8 at 7:49 AM
News IconStock Trading Above Moving Averages: BioMarin Pharmaceutical ... - Post News (NASDAQ:BMRN) - September 7 at 8:59 PM logoBioMarin's (BMRN) Brineura Review Period Extended by FDA - Nasdaq (NASDAQ:BMRN) - September 7 at 8:59 PM


BioMarin Pharmaceutical (NASDAQ:BMRN) Chart for Monday, September, 26, 2016

Last Updated on 9/26/2016 by Staff